Pay in 4 interest-free payments of $5.79 Learn more
Ships within 48 hours · Estimated delivery Nov 3 - Nov 8
Pharmacodynamic Biomarkers in the Phase 1 Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia
Targeting GSH synthesis/utilization therefore represents a potential means of rendering tumor cells more susceptible to different treatment options such as chemotherapy and radiotherapy
IGF-1 LR3 offers wider, longer-lasting anabolic benefits than shorter-acting IGF-1 versions, which can necessitate frequent dosage or target localized applications
Cytokine effects in acute leukemia analysis of cytokine receptors cell cycle kinetics and clonality in normal and leukemic target cells
US$ 20.21
US$ 24.72
US$ 24.64
US$ 21.67
US$ 29.50
